
Published simultaneously with ISGD Clinical Trials Summit 2026, a #ASNJASN study found that finerenone preserved kidney function and produced clinically meaningful reductions in proteinuria in participants with FSGS in FIND-CKD. kidney.pub/JASN1333

Nephrologist, physician-scientist. Director, Division of Nephrology, Jared Grantham Kidney Institute, University of Kansas @KUNeph Opinions are my own

Published simultaneously with ISGD Clinical Trials Summit 2026, a #ASNJASN study found that finerenone preserved kidney function and produced clinically meaningful reductions in proteinuria in participants with FSGS in FIND-CKD. kidney.pub/JASN1333

Could PDGF-C be a new target for kidney disease treatment? Blocking this pathway reduced kidney inflammation, scarring, and loss of function in preclinical studies, according to #BasicResearch in #ASNJASN. kidney.pub/JASN1274


#ASNJASN: A new approach for ADPKD? Low-dose abemaciclib reduced cyst growth more effectively than tolvaptan in mouse models and even reversed disease progression in some animals by restoring polycystin function in kidney cilia. #BasicResearch bit.ly/JASN1269

New ASN Kidney Translation Podcast episode reviews 2 late-breaking clinical trials published simultaneously with #KidneyWk: empagliflozin in ADPKD and upacicalcet for secondary hyperparathyroidism in hemodialysis. kidney.pub/KTPOD102426

Advancing kidney therapeutics and amplifying patient voices, Aliza Thompson, MD, MS, is the inaugural recipient of the joint ASN-NKF award. Her leadership at the FDA has helped move kidney disease drug development forward. #ASNKidneyNews kidney.pub/KN1810-27

Advancing ADPKD Research! Dr. Stephen Seliger presented collaborative research on empagliflozin therapy in ADPKD at ASN Kidney Week 2026. Congratulations to Drs. Seliger and Chonchol! Publication: pubmed.ncbi.nlm.nih.gov/4292… #ADPKD #KidneyResearch

Our kidneys have their own “body clock.” A #basicresearch study in #ASNKidney360 suggests that in ADPKD, that clock may be disrupted as cysts grow. Researchers hope these findings could lead to new ways to protect kidney function in the future. kidney.pub/KID1347

New in #ASNJASN and simultaneously published with #KidneyWk: Study found empagliflozin 25 mg once daily for 12 months was safe & well-tolerated in adults with ADPKD at high risk for rapid progression. Those treated with empagliflozin had greater increase in kidney volume kidney.pub/JASN1271

Stronger together!!! Excellent day with The PKD RRC team at ASN kidney week. @American society of Nephrology @pkdresearch

University of Kansas nephrology @KUNeph @KUJGKI are in Denver for @ASNKidney #KidneyWk

Basic Research published in #ASNJASN identified a protein called ARL13B that helps drive cyst growth in polycystic kidney disease. In mice, blocking this protein reduced cyst growth and improved kidney health, suggesting it could be a possible target for future treatments. kidney.pub/JASN1238

New research published in #ASNJASN helps explain why people with chronic kidney disease are more prone to blood clots and points to a potential new target for preventing these serious complications. kidney.pub/JASN1203

Could a novel CHAR T-cell therapy provide a targeted way to desensitize kidney transplant candidates with HLA-DQ antibodies? Read #BasicResearch #ASNJASN to find out. kidney.pub/JASN1244

Huge disappointment. High hopes...dashed
Following a recommendation from the DMD Boehringer Ingelheim has decided to discontinue the EASi-KIDNEY trial (NCT06531824) Testing vicadrostat (BI 690517), in combination with empagliflozin vs empagliflozin alone, could slow CKD and ⬇️ CV events boehringer-ingelheim.com/hum…

Some people with HIV who carry high-risk APOL1 genes may be less likely to develop kidney disease if they also have the APOL1 p.N264K genetic variant. This finding in #ASNJASN may help doctors better understand an individual's kidney disease risk in the future. kidney.pub/JASN1235